“Does ath434 slow clinical progression?On this important clinical measure, ATH434 demonstrated 48% slowing of clinical progression at the 50 mg dose (p=0.03)^ and 29% slowing of clinical progression at the 75 mg dose (p=0.2) at Week 52 when compared with placebo. The 75 mg dose group showed a 62% slowing of progression (p=0.05) at Week 26.”
The above tells me Ath434 for MSA was a success
Ann: Alterity Phase 2 Presentation at AAN 2025, page-37
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $12.66K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4352071 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 8220041 | 19 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |